nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

08.03.2023 | Retinal Disorders

Oral minocycline for the treatment of retinitis pigmentosa–associated cystoid macular edema: results of a phase I/II clinical trial

verfasst von: Amisha D. Dave, Katherine G. Chen, Trent Tsun-Kang Chiang, Janani Singaravelu, Jason A. Alvarez, Wai T. Wong, Catherine A. Cukras

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The etiology of retinitis pigmentosa (RP)–associated cystoid macular edema (CME) has been related to retinal neuroinflammation and microglial activation. Minocycline, a drug FDA-approved for anti-microbial indications, also inhibits microglial activation and expression of inflammatory mediators. This study investigates the safety and efficacy of oral minocycline as primary treatment for RP-associated CME.

Methods

A single-center, prospective, open-label phase I/II clinical trial enrolled five participants with RP-associated CME. Participants had lead-in assessments prior to the initiation of oral minocycline 100 mg twice daily for 12 months. Main outcome variables included changes in best-corrected visual acuity (BCVA) and retinal central subfield thickness (CST) measured using spectral domain optical coherence tomography relative to mean of pre-treatment measurements.

Results

The study drug was well tolerated and not associated with any severe adverse events. No significant changes in mean BCVA from study baseline were noted in either the study eye (+ 0.7 ± 4.1 letters at 6 months, − 1.1 ± 1.7 letters at 12 months) or the qualifying fellow eye (− 0.3 ± 3.4 letters at 6 months, − 0.3 ± 4.6 letters at 12 months) (p > 0.05 for all comparisons). Mean percentage changes in CST from baseline however decreased progressively with treatment (decreases at 6 and 12 months: study eyes 3.9 and 9.8%; qualifying fellow eyes 1.4 and 7.7%). Considering all eyes (n = 10), mean percentage CST decrease at 6 and 12 months was 2.7 ± 9.5% (p = 0.39) and 8.7 ± 9.5% (p = 0.02) respectively.

Conclusion

Oral minocycline administration over 12 months was associated with no significant changes in mean BCVA and a small but progressive decrease in mean CST.

Trial registration

NCT02140164 (05/2014).

Nur mit Berechtigung zugänglich

Hartong DT, Berson EL, Dryja TP (2006) Retinitis pigmentosa. Lancet 368:1795–1809. https://doi.org/10.1016/S0140-6736(06)69740-7CrossRefPubMed

Daiger SP, Sullivan LS, Bowne SJ (2013) Genes and mutations causing retinitis pigmentosa. Clin Genet 84:132–141. https://doi.org/10.1111/cge.12203CrossRefPubMed

Adackapara CA, Sunness JS, Dibernardo CW, Melia BM, Dagnelie G (2008) Prevalence of cystoid macular edema and stability in oct retinal thickness in eyes with retinitis pigmentosa during a 48-week lutein trial. Retina 28:103–110. https://doi.org/10.1097/IAE.0b013e31809862aaCrossRefPubMed

Hajali M, Fishman GA (2009) The prevalence of cystoid macular oedema on optical coherence tomography in retinitis pigmentosa patients without cystic changes on fundus examination. Eye (Lond) 23:915–919. https://doi.org/10.1038/eye.2008.110CrossRefPubMed

Hajali M, Fishman GA, Anderson RJ (2008) The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol 92:1065–1068. https://doi.org/10.1136/bjo.2008.138560CrossRefPubMed

Testa F, Rossi S, Colucci R, Gallo B, Di Iorio V, della Corte M, Azzolini C, Melillo P, Simonelli F (2014) Macular abnormalities in Italian patients with retinitis pigmentosa. Br J Ophthalmol 98:946–950. https://doi.org/10.1136/bjophthalmol-2013-304082CrossRefPubMed

Karasu B (2020) Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors. Int Ophthalmol 40:677–687. https://doi.org/10.1007/s10792-019-01228-zCrossRefPubMed

Blank T, Goldmann T, Koch M, Amann L, Schon C, Bonin M, Pang S, Prinz M, Burnet M, Wagner JE, Biel M, Michalakis S (2017) Early microglia activation precedes photoreceptor degeneration in a mouse model of CNGB1-linked retinitis pigmentosa. Front Immunol 8:1930. https://doi.org/10.3389/fimmu.2017.01930CrossRefPubMed

Zhao L, Zabel MK, Wang X, Ma W, Shah P, Fariss RN, Qian H, Parkhurst CN, Gan WB, Wong WT (2015) Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration. EMBO Mol Med 7:1179–1197. https://doi.org/10.15252/emmm.201505298CrossRefPubMedPubMedCentral

10.

Peng B, Xiao J, Wang K, So KF, Tipoe GL, Lin B (2014) Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa. J Neurosci 34:8139–8150. https://doi.org/10.1523/JNEUROSCI.5200-13.2014CrossRefPubMedPubMedCentral

11.

Cukras CA, Petrou P, Chew EY, Meyerle CB, Wong WT (2012) Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci 53:3865–3874. https://doi.org/10.1167/iovs.11-9413CrossRefPubMedPubMedCentral

12.

Chung YR, Kim YH, Lee SY, Byeon HE, Lee K (2019) Insights into the pathogenesis of cystoid macular edema: leukostasis and related cytokines. Int J Ophthalmol 12:1202–1208. https://doi.org/10.18240/ijo.2019.07.23CrossRefPubMedPubMedCentral

13.

Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Enaida H, Ishibashi T (2013) Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 120:e5-12. https://doi.org/10.1016/j.ophtha.2012.07.008CrossRefPubMed

14.

Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J (1998) Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95:15769–15774. https://doi.org/10.1073/pnas.95.26.15769CrossRefPubMedPubMedCentral

15.

Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96:13496–13500. https://doi.org/10.1073/pnas.96.23.13496CrossRefPubMedPubMedCentral

16.

Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, Levison SW (2005) Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54:1559–1565. https://doi.org/10.2337/diabetes.54.5.1559CrossRefPubMed

17.

Genead MA, Fishman GA (2010) Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Arch Ophthalmol 128:1146–1150. https://doi.org/10.1001/archophthalmol.2010.172CrossRefPubMedPubMedCentral

18.

Fishman GA, Apushkin MA (2007) Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 91:743–745. https://doi.org/10.1136/bjo.2006.107466CrossRefPubMedPubMedCentral

19.

Fishman GA, Gilbert LD, Anderson RJ, Marmor MF, Weleber RG, Viana MA (1994) Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology 101:687–693. https://doi.org/10.1016/s0161-6420(94)31277-2CrossRefPubMed

20.

Fishman GA, Gilbert LD, Fiscella RG, Kimura AE, Jampol LM (1989) Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol 107:1445–1452. https://doi.org/10.1001/archopht.1989.01070020519031CrossRefPubMed

21.

Fishman GA, Glenn AM, Gilbert LD (1993) Rebound of macular edema with continued use of methazolamide in patients with retinitis pigmentosa. Arch Ophthalmol 111:1640–1646. https://doi.org/10.1001/archopht.1993.01090120062023CrossRefPubMed

22.

Asahi MG, BobarnacDogaru GL, Onishi SM, Gallemore RP (2015) Strong topical steroid, NSAID, and carbonic anhydrase inhibitor cocktail for treatment of cystoid macular edema. Int Med Case Rep J 8:305–312. https://doi.org/10.2147/IMCRJ.S92794CrossRefPubMedPubMedCentral

23.

Ikeda Y, Hisatomi T, Yoshida N, Notomi S, Murakami Y, Enaida H, Ishibashi T (2012) The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 250:809–814. https://doi.org/10.1007/s00417-011-1904-5CrossRefPubMed

24.

Liew G, Moore AT, Webster AR, Michaelides M (2015) Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa. Invest Ophthalmol Vis Sci 56:1531–1536. https://doi.org/10.1167/iovs.14-15995CrossRefPubMed

25.

Yeo JH, Min CH, Yoon YH (2022) Effect of oral carbonic anhydrase inhibitor on cystoid macular edema associated with retinitis pigmentosa: an OCT and OCT angiography study. Retina 42:1796–1804. https://doi.org/10.1097/IAE.0000000000003531CrossRefPubMedPubMedCentral

26.

Shimokawa S, Murakami Y, Fujiwara K, Funatsu J, Nakatake S, Koyanagi Y, Akiyama M, Yoshida N, Takeda A, Ikeda Y, Sonoda KH (2022) Recurrence rate of cystoid macular edema with topical dorzolamide treatment and its risk factors in retinitis pigmentosa. Retina 42:168–173. https://doi.org/10.1097/IAE.0000000000003286CrossRefPubMed

27.

Kitahata S, Hirami Y, Takagi S, Kime C, Fujihara M, Kurimoto Y, Takahashi M (2018) Efficacy of additional topical betamethasone in persistent cystoid macular oedema after carbonic anhydrase inhibitor treatments in retinitis pigmentosa. BMJ Open Ophthalmol 3:e000107. https://doi.org/10.1136/bmjophth-2017-000107CrossRefPubMedPubMedCentral

28.

Park UC, Park JH, Ma DJ, Cho IH, Oh BL, Yu HG (2020) A randomized paired-eye trial of intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa. Retina 40:1359–1366. https://doi.org/10.1097/IAE.0000000000002589CrossRefPubMed

29.

Veritti D, Sarao V, De Nadai K, Chizzolini M, Parmeggiani F, Perissin L, Lanzetta P (2020) Dexamethasone implant produces better outcomes than oral acetazolamide in patients with cystoid macular edema secondary to retinitis pigmentosa. J Ocul Pharmacol Ther 36:190–197. https://doi.org/10.1089/jop.2018.0153CrossRefPubMed

30.

Strong SA, Peto T, Bunce C, Xing W, Georgiou M, Esposti SD, Kalitzeos A, Webster A, Michaelides M (2020) Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa. Br J Ophthalmol 104:1203–1208. https://doi.org/10.1136/bjophthalmol-2019-315152CrossRefPubMed

31.

Shah CR, Brent MH (2010) Treatment of retinitis pigmentosa-related cystoid macular edema with intravitreous ranibizumab. Retin Cases Brief Rep 4:291–293. https://doi.org/10.1097/ICB.0b013e3181af7b6cCrossRefPubMed

Titel: Oral minocycline for the treatment of retinitis pigmentosa–associated cystoid macular edema: results of a phase I/II clinical trial
verfasst von: Amisha D. Dave
Katherine G. Chen
Trent Tsun-Kang Chiang
Janani Singaravelu
Jason A. Alvarez
Wai T. Wong
Catherine A. Cukras
Publikationsdatum: 08.03.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 8/2023
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-023-05986-6

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Oral minocycline for the treatment of retinitis pigmentosa–associated cystoid macular edema: results of a phase I/II clinical trial

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Foldable capsular vitreous body indications, complications, and outcomes: a systematic review

Effect of statins on the age of onset of age-related macular degeneration

Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy

The impact of case complexity in resident-performed cataract surgery

The outcomes of a low-cost, non-valved glaucoma drainage device using mitomycin-C: 1-year results

Pediatric herpes zoster ophthalmicus: a systematic review

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde